Skip to main content
Positive Results From Phase 2 Trial Support Potential New Option for Control of CIDP
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Positive Results From Phase 2 Trial Support Potential New Option for Control of CIDP
User login
Username
Password
Reset your password
Concept
Lead
score
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1
1
Minnesota
0
0.58
Immunoglobulin G (IgG)
0
0.46
Corticosteroids
0
0.44
Immunoglobulin A (IgA)
0
0.44
Intravenous Immunoglobulin (IVIG)
0
0.42
Disability
0
0.29
Adverse Effects
0
0.15
Autoimmune Disease
0
0.15
Demyelination
0
0.15
Intravenous
0
0.15
Neuropathy
0
0.15
Plasmapheresis
0
0.15
Steroids
0
0.15
Headache
0
0.07
Muscular Atrophy
0
0.07
Myasthenia Gravis
0
0.07
Patient Safety
0
0.07
Specialty
Lead
score
Neurology & Neurosurgery
1
1
Allergy & Clinical Immunology
0
0.39
Pharmacist
0
0.31
Family Medicine/Primary Care
0
0.2
Rheumatology
0
0.19
Internal Medicine
0
0.12
Edit Tags